.Pharmacolibrary.Drugs.ATC.A.A10BG02 .Pharmacolibrary.Drugs.ATC.A.A10BG02| name: | Rosiglitazone |
| ATC code: | A10BG02 | route: | oral |
| n-compartments | 2 |
Rosiglitazone is an oral antidiabetic agent of the thiazolidinedione class. It functions as an insulin sensitizer by acting as a selective agonist at the peroxisome proliferator-activated receptor gamma (PPARγ). It is primarily used to treat type 2 diabetes mellitus to improve glycemic control. Due to concerns about cardiovascular safety, its use has been restricted in several regions.
Pharmacokinetic parameters in healthy adults after single oral dose administration, both male and female subjects.
Chu, KM, et al., & Hsiong, CH (2007). Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 10(4) 411–419. DOI:10.18433/j3159d PUBMED:https://pubmed.ncbi.nlm.nih.gov/18261363
Kirchheiner, J, et al., & Brockmöller, J (2005). Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clinical pharmacokinetics 44(12) 1209–1225. DOI:10.2165/00003088-200544120-00002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16372821
Aquilante, CL, et al., & Kosmiski, LA (2008). Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers. Human genomics 3(1) 7–16. DOI:10.1186/1479-7364-3-1-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19129086